Can-Fite BioPharma Ltd. (AMEX: CANF) stock fell -6.32% on Tuesday to $4.74 against a previous-day closing price of $5.06. With 1.34 million shares changed hands, the volume of the stock remained heavier than its average volume of 20580.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $5.3599 whereas the lowest price it dropped to was $4.4400. The 52-week range on CANF shows that it touched its highest point at $12.90 and its lowest point at $4.57 during that stretch. It currently has a 1-year price target of $66.25.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CANF was down-trending over the past week, with a drop of -15.36%, but this was down by -30.29% over a month. Three-month performance dropped to -36.54% while six-month performance fell -44.24%. The stock lost -60.83% in the past year, while it has lost -22.68% so far this year. A look at the trailing 12-month EPS for CANF yields -0.75 with Next year EPS estimates of -5.50. For the next quarter, that number is -1.10. This implies an EPS growth rate of 47.20% for this year and -15.80% for next year.
Float and Shares Shorts:
At present, 3.14 million CANF shares are outstanding with a float of 3.14 million shares on hand for trading. On Oct 13, 2022, short shares totaled 0.44 million, which was 1.63% higher than short shares on Sep 14, 2022. In addition to Dr. Pnina Fishman Ph.D. as the firm’s Scientific Founder, CEO & Director, Mr. Motti Farbstein serves as its Chief Operating & Financial Officer.
Through their ownership of 1.85% of CANF’s outstanding shares, institutional investors have minority control over the company. Other institutions hold — of CANF, in contrast to — held by mutual funds. Shares owned by individuals account for –.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CANF since 2 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CANF analysts setting a high price target of $82.57 and a low target of $80.07, the average target price over the next 12 months is $81.32. Based on these targets, CANF could surge 1641.98% to reach the target high and rise by 1589.24% to reach the target low. Reaching the average price target will result in a growth of 1615.61% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. CANF will report FY 2022 earnings on 03/21/2024. Analysts have provided yearly estimates in a range of -$0.11 being high and -$7.01 being low. For CANF, this leads to a yearly average estimate of -$3.56. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Can-Fite BioPharma Ltd. surprised analysts by -$0.55 when it reported -$1.45 EPS against a consensus estimate of -$0.90. The surprise factor in the prior quarter was -$0.30. Based on analyst estimates, the high estimate for the next quarter is -$0.20 and the low estimate is -$1.80. The average estimate for the next quarter is thus -$1.00.